Cerebrolysin vs N-Acetyl Selank
A neutral, side-by-side comparison of two nootropic & cognitive peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Cerebrolysin
Cerebrolysin is a brain-derived peptide mixture produced by controlled enzymatic breakdown of porcine brain proteins. Unlike synthetic peptides, it is a complex of ~25% low-molecular-weight neuropeptides and ~75% free amino acids, with the bioactive peptide fraction mimicking the endogenous neurotrophic factors BDNF, NGF, GDNF, and CNTF in their mechanisms. It has a 30+ year clinical history in Eastern Europe and Asia for stroke recovery, traumatic brain injury, Alzheimer's disease, and vascular dementia — with a substantial human trial database.
Full profileN-Acetyl Selank
Acetylated variant of Selank with enhanced stability and bioavailability. The N-acetyl modification protects the peptide from rapid enzymatic degradation, extending its active half-life relative to standard Selank. Provides anxiolytic, nootropic, and immunomodulatory effects comparable to or exceeding standard Selank with potentially greater duration from each dose.
Full profile| Cerebrolysin | N-Acetyl Selank | |
|---|---|---|
| Category | Nootropic & Cognitive | Nootropic & Cognitive |
| Also known as | FPF 1070, EBEWE Cerebrolysin, Brain-derived peptide mixture | Selank-A, N-Ac-Selank, acetylated selank, N-acetyl selank |
| Evidence | Research-stage | Research-stage |
| Dosing range | 5mL–30mL mL, Daily for 10–20 day courses (IV preferred in clinical use); SQ/IM for research access | 100mcg–500mcg mcg, 1–2x daily intranasal |
| Administration | Intravenous infusion (clinical standard — dilute in 100mL saline over 15–30 min), Intramuscular injection (research use — lower bioavailability), Subcutaneous injection (less common) | Intranasal spray, Subcutaneous injection |
| Key side effects | Injection site pain (IM route), Hyperthermia / fever (rare, higher doses), Agitation or anxiety (uncommon), Nausea | Mild sedation (acute), Fatigue, Headache (rare), Nasal irritation (intranasal route) |
| Cited sources | 3 references | 2 references |
Key differences
- Administration: Cerebrolysin — Intravenous infusion (clinical standard — dilute in 100mL saline over 15–30 min), Intramuscular injection (research use — lower bioavailability), Subcutaneous injection (less common); N-Acetyl Selank — Intranasal spray, Subcutaneous injection.
- Dosing units differ: Cerebrolysin is dosed in mL, N-Acetyl Selank in mcg — they operate at different scales.
- Frequency: Cerebrolysin is typically Daily for 10–20 day courses (IV preferred in clinical use); SQ/IM for research access; N-Acetyl Selank is 1–2x daily intranasal.
- Research depth: this profile cites 3 sources for Cerebrolysin vs 2 for N-Acetyl Selank.
How each works
Cerebrolysin
Cerebrolysin's neuroprotective effects have been demonstrated in over 100 clinical trials, though most are from Eastern European and Asian centers with varying methodological quality. The CACTUS trial (N=256, multicenter) showed significant improvement in cognitive outcomes after ischemic stroke vs placebo. The ARTIST trials evaluated Cerebrolysin for Alzheimer's disease with mixed results. Meta-analyses of stroke and dementia trials generally support modest-to-moderate benefit. Mechanistically, the peptide fraction upregulates BDNF/NGF signaling, reduces excitotoxicity, inhibits caspase-3, and promotes synaptogenesis in animal and in vitro models.
N-Acetyl Selank
N-Acetyl Selank shares Selank's core mechanism — BDNF/NGF upregulation, enkephalinase inhibition, and GABA-A receptor complex modulation — with improved metabolic stability from the N-terminal acetyl group. The acetyl modification protects against aminopeptidase N and angiotensin-converting enzyme cleavage, extending the peptide's active residence time in neural tissue after intranasal administration.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.